Pill Identifier App

Calvenza EIV/EHV (Canada)

This page contains information on Calvenza EIV/EHV for veterinary use.
The information provided typically includes the following:
  • Calvenza EIV/EHV Indications
  • Warnings and cautions for Calvenza EIV/EHV
  • Direction and dosage information for Calvenza EIV/EHV

Calvenza EIV/EHV

This treatment applies to the following species:
Manufacturer: Boehringer

Equine Rhinopneumonitis-Influenza Vaccine

Killed Virus

Veterinary Use Only

Calvenza EIV/EHV Indications

For the vaccination of healthy, susceptible horses 6 months of age or older, including pregnant mares, as an aid in the reduction of respiratory diseases caused by equine herpesvirus type 1 (EHV-1) and type 4 (EHV-4), and by equine influenza virus types A2 North American and A2 Eurasian.

Administration and Dosage: Shake well before use. Using aseptic technique, vaccinate horses intramuscularly with a 2 mL dose. Administer a second 2 mL dose intramuscularly in 3-4 weeks using a different injection site. Administer a third 2 mL dose in 3-4 weeks by either the intramuscular or intranasal route.


Store at 2-7°C. Do not freeze. Use entire contents when first opened. Do not vaccinate within 21 days before slaughter. Anaphylactoid reactions may occur. Antidote: Epinephrine.

Preservatives: Gentamicin and thimerosal.

Manufactured by: Boehringer Ingelheim Vetmedica, Inc., St. Joseph, Missouri 64506 U.S.A.

US Vet. Lic. No. 124

Manufactured for: Boehringer Ingelheim (Canada) Ltd., Burlington, Ontario L7L 5H4

2 mL syringe


10 Doses/20 mL


NAC No.: 12300455

Customer Care No.:   800-567-1885
Technical Services No.:   1-877-565-5501
Website:   www.boehringer-ingelheim.ca
Every effort has been made to ensure the accuracy of the Calvenza EIV/EHV information published above. However, it remains the responsibility of the readers to familiarize themselves with the product information contained on the Canadian product label or package insert.

Copyright © 2015 North American Compendiums. Updated: 2014-12-03